Eur Rev Med Pharmacol Sci:研究揭示LncRNA-H19通过靶向miR-29a-3p抑制急性髓细胞白血病细胞的凋亡

2019-08-08 不详 网络

本研究旨在探讨lncRNA-H19通过Wnt信号通路对急性髓系白血病(AML)细胞增殖和凋亡的影响。从40名AML患者收集血样。培养AML细胞。使用细胞计数试剂盒-8(CCK-8)检测细胞增殖,流式细胞术用于分析细胞周期并确定细胞凋亡率。此外,通过双荧光素酶报告基因检测法检测lncRNA-H19的作用靶标,并进行蛋白质印迹以检测蛋白质水平的变化。结果显示,AML患者中lncRNA-H19的表达明显

本研究旨在探讨lncRNA-H19通过Wnt信号通路对急性髓系白血病(AML)细胞增殖和凋亡的影响。

从40名AML患者收集血样。培养AML细胞。使用细胞计数试剂盒-8(CCK-8)检测细胞增殖,流式细胞术用于分析细胞周期并确定细胞凋亡率。此外,通过双荧光素酶报告基因检测法检测lncRNA-H19的作用靶标,并进行蛋白质印迹以检测蛋白质水平的变化。

结果显示,AML患者中lncRNA-H19的表达明显高于正常对照,并且与人胚肾(HEK)-293T细胞相比,AML细胞Kasumi-1表现出lncRNA-H19的表达增加。LncRNA-H19可以促进细胞增殖,但抑制细胞凋亡。它以靶向方式与miR-29a-3p结合。并且AML患者中miR-29a-3p的表达水平明显低于正常对照组。miR-29a-3p被抑制后,核内β-连环蛋白的表达显著增加,Wnt /β-catenin通路关键分子T细胞因子(TCF)和淋巴增强因子1(LEF1)明显上调。miR-29a-3p的下调。

综上所述,该研究结果表明,LncRNA-H19靶向miR-29a-3p以促进AML细胞的增殖,但通过Wnt/β-连环蛋白信号传导通路抑制细胞凋亡。

原始出处:

Zhao TT, Liu X. LncRNA-H19 inhibits apoptosis of acute myeloid leukemia cells via targeting miR-29a-3p. Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):224-231. doi: 10.26355/eurrev_201908_18651.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908557, encodeId=a5ce190855e45, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 20 06:54:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005714, encodeId=12892005e14af, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Feb 27 23:54:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649714, encodeId=5aa41649e14ec, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Fri Aug 09 18:54:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787626, encodeId=eb4a1e8762649, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Sep 16 14:54:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822174, encodeId=eeaf18221e47d, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 28 12:54:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996308, encodeId=d753199630846, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 30 22:54:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930725, encodeId=3cd21930e25b4, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Oct 26 14:54:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788371, encodeId=dd071e88371ef, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Jul 16 11:54:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301916, encodeId=c5221301916a0, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468207, encodeId=ded7146820e91, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908557, encodeId=a5ce190855e45, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 20 06:54:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005714, encodeId=12892005e14af, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Feb 27 23:54:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649714, encodeId=5aa41649e14ec, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Fri Aug 09 18:54:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787626, encodeId=eb4a1e8762649, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Sep 16 14:54:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822174, encodeId=eeaf18221e47d, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 28 12:54:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996308, encodeId=d753199630846, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 30 22:54:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930725, encodeId=3cd21930e25b4, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Oct 26 14:54:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788371, encodeId=dd071e88371ef, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Jul 16 11:54:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301916, encodeId=c5221301916a0, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468207, encodeId=ded7146820e91, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908557, encodeId=a5ce190855e45, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 20 06:54:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005714, encodeId=12892005e14af, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Feb 27 23:54:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649714, encodeId=5aa41649e14ec, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Fri Aug 09 18:54:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787626, encodeId=eb4a1e8762649, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Sep 16 14:54:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822174, encodeId=eeaf18221e47d, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 28 12:54:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996308, encodeId=d753199630846, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 30 22:54:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930725, encodeId=3cd21930e25b4, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Oct 26 14:54:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788371, encodeId=dd071e88371ef, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Jul 16 11:54:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301916, encodeId=c5221301916a0, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468207, encodeId=ded7146820e91, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
    2019-08-09 tidiq
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908557, encodeId=a5ce190855e45, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 20 06:54:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005714, encodeId=12892005e14af, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Feb 27 23:54:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649714, encodeId=5aa41649e14ec, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Fri Aug 09 18:54:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787626, encodeId=eb4a1e8762649, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Sep 16 14:54:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822174, encodeId=eeaf18221e47d, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 28 12:54:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996308, encodeId=d753199630846, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 30 22:54:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930725, encodeId=3cd21930e25b4, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Oct 26 14:54:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788371, encodeId=dd071e88371ef, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Jul 16 11:54:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301916, encodeId=c5221301916a0, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468207, encodeId=ded7146820e91, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
    2019-09-16 jj000001
  5. [GetPortalCommentsPageByObjectIdResponse(id=1908557, encodeId=a5ce190855e45, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 20 06:54:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005714, encodeId=12892005e14af, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Feb 27 23:54:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649714, encodeId=5aa41649e14ec, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Fri Aug 09 18:54:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787626, encodeId=eb4a1e8762649, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Sep 16 14:54:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822174, encodeId=eeaf18221e47d, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 28 12:54:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996308, encodeId=d753199630846, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 30 22:54:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930725, encodeId=3cd21930e25b4, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Oct 26 14:54:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788371, encodeId=dd071e88371ef, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Jul 16 11:54:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301916, encodeId=c5221301916a0, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468207, encodeId=ded7146820e91, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1908557, encodeId=a5ce190855e45, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 20 06:54:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005714, encodeId=12892005e14af, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Feb 27 23:54:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649714, encodeId=5aa41649e14ec, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Fri Aug 09 18:54:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787626, encodeId=eb4a1e8762649, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Sep 16 14:54:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822174, encodeId=eeaf18221e47d, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 28 12:54:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996308, encodeId=d753199630846, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 30 22:54:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930725, encodeId=3cd21930e25b4, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Oct 26 14:54:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788371, encodeId=dd071e88371ef, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Jul 16 11:54:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301916, encodeId=c5221301916a0, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468207, encodeId=ded7146820e91, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
    2019-08-30 yb6560
  7. [GetPortalCommentsPageByObjectIdResponse(id=1908557, encodeId=a5ce190855e45, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 20 06:54:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005714, encodeId=12892005e14af, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Feb 27 23:54:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649714, encodeId=5aa41649e14ec, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Fri Aug 09 18:54:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787626, encodeId=eb4a1e8762649, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Sep 16 14:54:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822174, encodeId=eeaf18221e47d, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 28 12:54:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996308, encodeId=d753199630846, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 30 22:54:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930725, encodeId=3cd21930e25b4, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Oct 26 14:54:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788371, encodeId=dd071e88371ef, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Jul 16 11:54:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301916, encodeId=c5221301916a0, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468207, encodeId=ded7146820e91, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
    2019-10-26 smallant2002
  8. [GetPortalCommentsPageByObjectIdResponse(id=1908557, encodeId=a5ce190855e45, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 20 06:54:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005714, encodeId=12892005e14af, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Feb 27 23:54:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649714, encodeId=5aa41649e14ec, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Fri Aug 09 18:54:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787626, encodeId=eb4a1e8762649, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Sep 16 14:54:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822174, encodeId=eeaf18221e47d, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 28 12:54:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996308, encodeId=d753199630846, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 30 22:54:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930725, encodeId=3cd21930e25b4, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Oct 26 14:54:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788371, encodeId=dd071e88371ef, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Jul 16 11:54:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301916, encodeId=c5221301916a0, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468207, encodeId=ded7146820e91, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1908557, encodeId=a5ce190855e45, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 20 06:54:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005714, encodeId=12892005e14af, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Feb 27 23:54:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649714, encodeId=5aa41649e14ec, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Fri Aug 09 18:54:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787626, encodeId=eb4a1e8762649, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Sep 16 14:54:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822174, encodeId=eeaf18221e47d, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 28 12:54:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996308, encodeId=d753199630846, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 30 22:54:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930725, encodeId=3cd21930e25b4, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Oct 26 14:54:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788371, encodeId=dd071e88371ef, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Jul 16 11:54:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301916, encodeId=c5221301916a0, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468207, encodeId=ded7146820e91, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
    2019-08-10 xzw113
  10. [GetPortalCommentsPageByObjectIdResponse(id=1908557, encodeId=a5ce190855e45, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Wed May 20 06:54:00 CST 2020, time=2020-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005714, encodeId=12892005e14af, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Feb 27 23:54:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649714, encodeId=5aa41649e14ec, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Fri Aug 09 18:54:00 CST 2019, time=2019-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787626, encodeId=eb4a1e8762649, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Sep 16 14:54:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822174, encodeId=eeaf18221e47d, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Oct 28 12:54:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996308, encodeId=d753199630846, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Fri Aug 30 22:54:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1930725, encodeId=3cd21930e25b4, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Sat Oct 26 14:54:00 CST 2019, time=2019-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788371, encodeId=dd071e88371ef, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu Jul 16 11:54:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301916, encodeId=c5221301916a0, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468207, encodeId=ded7146820e91, content=<a href='/topic/show?id=71c810212946' target=_blank style='color:#2F92EE;'>#髓细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102129, encryptionId=71c810212946, topicName=髓细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69e46898758, createdName=chengjn, createdTime=Sat Aug 10 10:54:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
    2019-08-10 chengjn